Programme
What DeSci means for this initiative
Early-intervention CHR-P research often needs careful, long studies that conventional venture timelines struggle to match. DeSci / DAO language here describes how we explain open science and community coordination — not a live invest product on this site. What is live, proposed, or undecided is labelled below. Clinical control stays with NWPharmaTech as pharmaceutical sponsor.
Proposed — not open for investment on this site. You cannot subscribe, pay, or connect a wallet here. Community ≠ investment rights. Any future financing would follow private legal processes for eligible investors only.
Why look beyond conventional funding alone?
We want specialist life-sciences capital and newer constituencies — including crypto-native family offices and mission-aligned DeSci supporters — to sit around a clear programme plan without weakening sponsor accountability.
How programme funding could work
We are evaluating a platform-supported route for eligible investors to help finance the CHR-P research programme, including a permissioned digital record of participation at closing where that proves feasible. If a platform path cannot meet legal, operational or investor-access requirements, a conventional private placement with a legal investor register remains the fallback. These are development objectives, not live offering terms. Neither path is available on this website: production investment, payment and token issuance remain inactive. Community updates and discussion are separate from any regulated investment process.
- A dedicated programme vehicle (proposed) for CHR-P programme economics — separate from NWPharmaTech parent equity.
- Transparent use of proceeds toward a defined scientific package. Approximately US$10 million is a planning target only — not money raised, and not a claim that capital fully funds the Phase 2B trial.
- Register as legal truth. Any permissioned digital representation, if used, would only mirror the register (register beats token). Providers and timing remain under evaluation — no vendor is crowned here.
What stays with NWPharmaTech
Clinical protocol, safety, manufacturing quality and regulatory filings remain with NWPharmaTech as pharmaceutical sponsor, together with investigators, ethics committees and regulators as applicable. Investors would not vote on dose, endpoints or medical decisions, and would not own the medicine or patient data.
How most visitors can take part
Most visitors are not investors — and should not need to be. You can read the science, follow articles, and send research or collaboration enquiries. See Community for what is available today.